How Much Longer Will We Put Up With $100,000 Cancer Drugs?

Publication date: 9 February 2017
Source:Cell, Volume 168, Issue 4
Author(s): Paul Workman, Giulio F. Draetta, Jan H.M. Schellens, René Bernards
The spiraling cost of new drugs mandates a fundamentally different approach to keep lifesaving therapies affordable for cancer patients. We call here for the formation of new relationships between academic drug discovery centers and commercial partners, which can accelerate the development of truly transformative drugs at sustainable prices.

Teaser

The spiraling cost of new drugs mandates a fundamentally different approach to keep lifesaving therapies affordable for cancer patients. We call here for the formation of new relationships between academic drug discovery centers and commercial partners, which can accelerate the development of truly transformative drugs at sustainable prices.


from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kc6DgM
via IFTTT